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OBJECTIVES: Estimate current healthcare costs for HCV and its consequences in a
large, US managed care organization (MCO). METHODS: Patients with ICD-9 diag-
nosis codes for Hepatitis C viral (HCV) infection (1st diagnosisindex date), age 18
years with 6 months of continuous enrollment were identified in a large, MCO
claims database from 1/1/2002 to 3/31/2010. HCV patients were matched 1:10 to
patients without an HCV diagnosis or advanced liver disease (ALD), based on gen-
der, age, index year (where synthetic index dateenrollment  median post-en-
rollment days to case index date), hospital referral region (HRR) state, pre-index
healthcare costs, alcoholism, HIV/AIDS, andmodified Charlson Comorbidity Index.
Cases were stratified by disease state: chronic HCV without liver involvement (C-
HCV), compensated cirrhosis (CC), decompensated cirrhosis (DC), hepatocellular
carcinoma (HCC), or liver transplant. Mean per-member per-year (PMPY) costs
were estimated post-index (total post-index cost of all patients /[sum of all post-
index days/365]). Incremental PMPY costs for HCV patients vs. matched controls
were estimated overall and by each disease state. RESULTS: 34,597 HCV patients
were matched to 330,435 controls. Mean age of cases was 49.9 (8.5) years; 62%
were female; 78% had C-HCV, 4% CC, 12% DC, 3% HCC, and 3% transplant. Incre-
mental costs vs. controls overall were $9,681 PMPY. Incremental PMPY costs for
patients with ALD were DC: $27,845, HCC: $43,671, and transplant: $93,609. For
patients without ALD, incremental PMPYs were C-HCV: $5,870, and CC: $5,330.
Incremental drug costs forHCV treatmentwere $2,739 overall, ranging from$1,893-
$8,736 for different states. C-HCV and CC drug costs were $2,659 and $3,102,
respectively. CONCLUSIONS: Current estimates of HCV cost burden to MCOs were
higher than previously reported and increased substantially with progression to
ALD. The higher estimated costs of managing chronic HCV were likely due to high
non-liver related costs among HCV patients or imprecise coding of CC.
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OBJECTIVES: HIV-infected patients are at an increased risk of cardiovascular dis-
eases (CVD), resulting in the need for integration of CVD screening into HIV treat-
ment guidelines. We evaluated different CVD screening strategies in HIV-infected
patients with regard to effectiveness, costs, and cost-effectiveness. METHODS:
Cost-effectiveness analysis using a microsimulation model reflecting coronary ar-
tery disease (CAD), myocardial dysfunction, and heart failure in HIV-positive men.
Data sources: Patient-level data from HIV-HEART study, literature, German reim-
bursement data. Time horizon: Diagnostic phase, lifetime. Perspective: Societal.
Interventions: No screening (SOC), ECGBNPwith echocardiographystress-ECG if
pathologic ECG or BNP (“Outpatient”), ECGBNPechocardiographystress-ECG
(“Cardiologist”), “Cardiologist” with coronary computed tomography angiography
if pathologic echocardiography or stress-ECG (“Cardiologist ”). Outcomes: Diag-
nostic results, discounted quality-adjusted life expectancy (QALE) and lifetime
costs, incremental cost-effectiveness ratio (ICER). RESULTS: The initial CAD prev-
alence in HIV-infected men aged 40 years was estimated at 5.9%. One-time “Out-
patient”, “Cardiologist”, and “Cardiologist ” screenings correctly diagnosed 7, 43,
and 48 out of 59 CAD patients per 1,000 patients at €46/person, €109/person, and
€429/person, respectively. The expected QALE was estimated at 16.54, 16.56, 16.71,
and 16.75 years for SOC, and one-time “Outpatient”, “Cardiologist”, and “Cardiolo-
gist” screenings atmean lifetime costs per patient of €321,348, €322,279, €327,670,
and €328,864, respectively. “Outpatient” and “Cardiologist” were extendedly dom-
inated by “Cardiologist ”. The ICER of “Cardiologist ” vs. SOC was €35,791 per
quality-adjusted life year (QALY). When screening frequency was varied between
one and five years at one-year intervals, “Cardiologist” was extendedly dominated
by “Cardiologist”. The predicted ICERs for the non-dominated strategies as com-
pared to SOC were €34,508, €40,489, and €49,373 per QALY for annual “Outpatient”
and “Cardiologist ” at 5- and 4-year intervals, respectively. CONCLUSIONS: Our
preliminary analyses suggest that integrating routine CVD screening into HIV
treatment guidelines could be clinically beneficial and cost-effective.
PODIUM SESSION II:
IMPACT OF MEDICATION COMPLIANCE
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OF PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB OR
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OBJECTIVES: Adalimumab and etanercept are patient self-administered biologic
agents used in rheumatoid arthritis (RA). Prescription refill gap analyses may be
conducted to understand patient refill behavior as a proxy for compliance. The
objective of this study was to evaluate gaps between prescription refills of adali-
mumab or etanercept across multiple databases and compare results of different
methodologies. METHODS: Data were obtained from three retrospective claims
databases (HealthCore Integrated Research Database-HIRD [adalimumab or etan-
ercept initiation 07/2004-10/2008], MarketScan Commercial and Medicare Supple-
mental Claims databases [01/2003-06/2008], and Wolters Kluwer Pharma Solu-
tions-WKPS database [01/2004-12/2008]). Inclusion criteria: 18 years old, 2 RA
diagnosis codes (ICD-9 code 714.xx), no biologic therapy 6 or 12 months prior to
current therapy, one year of treatment persistence (HIRD and MarketScan only),
and no selected inflammatory conditions. Mean gaps (days) in refills were calcu-
lated among all RA patients in MarketScan and WKPS, and calculated among only
those patients with 1 day of gap in HIRD. Analyses included the first 15 refill
periods. RESULTS: Data from 15,818 adalimumab and 25,175 etanercept patients
were analyzed. Mean adalimumab gaps spanned 1.3 to 8.4 and 6.8 to 11.4 days in
MarketScan and WKPS, respectively. Mean adalimumab gaps spanned 17.2 to 33.4
days in HIRD when calculated among only those patients with 1 day of gap in
refilling. Mean etanercept gaps spanned 1.3 to 10.9, 6.6 to 14.2, and 16.3 to 37.4 days
forMarketScan,WKPS, andHIRD, respectively.CONCLUSIONS:Results acrossmul-
tiple databases substantiate that refill gaps exist among adalimumab and etaner-
cept users during each refill period. The specific methodology for calculating refill
gaps should be considered. The extent of delayed refills may be underestimated
when calculated across an entire population, instead of only among those with
evidence of a gap. Further research is needed examining clinical and economic
consequences associated with therapy gaps.
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OBJECTIVES: Medication adherence has been linked to better health outcomes.
Therefore, a comprehensive understanding of the predictors of adherence is es-
sential for formulating adherence-improving strategies. Existingmethods have not
considered evaluation of heterogeneous impacts of predictors at different parts
(quantiles) of the adherence distribution as defined bymedication possession ratio.
Using the novel econometric framework of unconditional quantile regression
(UQR), this study assesses the heterogeneity of impacts of adherence predictors for
anAlzheimer’s disease (AD) population.METHODS:This retrospective claims anal-
ysis identified AD patients from a large US health plan that initiated oral AD ther-
apy (rivastigmine, donepezil, galantamine, or memantine) between 1/1/2006 and
12/31/2007. Baseline characteristics were assessed during the 6-month pre-index
period; medication adherence was assessed during the 1-year post-index period.
UQR was estimated at 10th, 20th, . . ., 90th quantiles. Predictors of adherence iden-
tified from the data included age, gender, indicator of mental health insurance
coverage, region, commercial vs. Medicare insurance, log cost, comorbidity, and
formulary tier for the AD medication. RESULTS: Baseline medication count was
positively associated with adherence (p0.05) in the upper half of the adherence
distribution. Having mental health coverage is negatively associated with adher-
ence in all but the 10th and 20th quantiles but the impact was substantially higher
in the first half of the adherence distribution. Baseline (log) cost was positively
associated with adherence in the 40th and upper quantiles of the adherence distri-
bution. For patients in the 80th and 90th quantiles, the number of baseline office
visits predicted lower adherence. Compared to patients from the East, patients
from the South were less likely to be adherent in the 60th and 70th quantiles.
CONCLUSIONS:The study results highlight the heterogeneity of impacts of various
adherence predictors – a predictor may be statistically significant only in specific
quantiles of the adherence distribution, and the impacts may vary substantially
between quantiles.
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OBJECTIVES: To investigate the impact of multiple medication compliance on the
occurrence of cardiovascular disease (CVD) outcomes using instrumental variables
(IV) to control for endogeneity bias. METHODS: We identified individuals who
newly start oral diabetes or hypertension medication therapy between July 2006
and June 2007 with the pre-existing comorbid hypertension or diabetes prescrip-
tion history during 6months of pre-index period using administrative claims from
amanaged care organization in southern California (N1565). Multiplemedication
compliance was defined as a proportion of days covered for both diabetes and
hypertension medications during three years of follow-up. Cardiovascular out-
comes included myocardial infarction, stroke, and peripheral vascular disease.
Instrumental variables estimation using physician related variables including a
dummy for the same prescribers for bothmedications, the percentage of follow-up
visit per physician, and the percentage of statin prescription per physician was
implemented. Parameter estimates were compared using probit and IV-probit
models.RESULTS:Mean complianceswere 0.636 (0.008) for diabetesmedications,
0.686 (0.008) for hypertension medications, and 0.527 (0.008) for both medica-
tions. After adjusting for age, gender, baseline clinical measures (Hemoglobin A1C,
blood pressure, and lipid), pre-existing condition (either diabetes or hypertension),
and Elixhauser-comorbidity, adherence to both medications was not significantly
associated with decreased CVD rate (0.0700.118, p0.554) based on probit
model. After controlling for endogeneity, however, the impact of multiple
medication adherence became statistically significant using IV-probit model
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(2.2700.345, p0.0001). IVs satisfied identification conditions individually and
as a group. The increasing multiple medication compliance from 50% to 80% was
associated with the reduction of the average probability of predicted CVD occur-
rence from 0.46 (0.091, p0.0001) to 1.14 (0.042, p0.0001) at the mean level
of covariates. CONCLUSIONS: After controlling for endogeneity bias, compliance
withmultiple medications was significantly associated with a decrease in the CVD
event rate with type II diabetes and comorbid hypertension.
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OBJECTIVES: To study the patterns of discontinuation of ACEI/ARB therapy and to
identify factors associated with discontinuation among post myocardial infarction
(MI) patients enrolled in Medicare.METHODS: This is a retrospective cohort study
utilizing the Medicare 5% national sample claims data for 2006-2007. Medicare
beneficiaries with continuous enrollment in Part A, B, and D in 2006-2007, and who
were hospitalized for an acute MI between January 1 and June 30 of 2006, were
identified using a validated algorithm, requiring a hospitalization episode 3 and
180 days with an ICD-9-CM of 410.x1 as primary or secondary diagnosis. Post-MI
patients with an ACEI/ARB prescription within 90 days of discharge were followed
to study patterns of discontinuation until December 31, 2007. Time to discontinu-
ation was defined as the days from initiation of therapy to a therapy gap of 90
days. Survival curves were constructed using the Kaplan-Meier technique, and
potential predictors of therapy discontinuation, including demographic character-
istics, comorbidities and concomitant medications were estimated using Cox pro-
portional hazards regression. RESULTS: Of the 1,949 subjects in the cohort, 66.1%
were females, 82.9% were Caucasian with a mean age of 78.6 (8.2) years. Approx-
imately, 20% of the patients discontinued therapy within six months and 45%
discontinued within a year. Caucasians were less likely to discontinue therapy as
compared to blacks (HR0.774; [0.638-0.939]; p0.0094). Among the comorbid con-
ditions, dyslipidemia (HR0.734; [0.612-0.880]; p0.0008), cerebrovascular disease
(HR1.124; [0.986-1.281]; p0.0806) and COPD (HR1.154; [1.013-1.316]; p0.0319)
were significant predictors of time to discontinuation. Patients on concomitant
beta-blocker (HR0.771; [0.627-0.949]; p0.0141) and statin (HR0.857; [0.736-
0.999]; p0.0491) therapy were less likely to discontinue ACEI/ARB therapy.
CONCLUSIONS: Many patients initiating ACEI/ARB treatment following MI fail to
consistently remain on therapy as is evident by the high rates of discontinuation
within a year. Several factors including race and comorbidities are potential pre-
dictors of this behavior.
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RESEARCH ON METHODS: ECONOMIC EVALUATIONS
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SYSTEMATIC REVIEW OF GUIDELINES FOR HEALTH ECONOMIC EVALUATIONS
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OBJECTIVES: Numerous guidelines on conduct and reporting of health economic
(HE) evaluations have been developed over several decades differing somewhat in
their objectives, scope and specific recommendations.We systematically reviewed
all accessible HE guidelines to identify commonalities and differences with respect
to type and content of recommendations. METHODS: A systematic search of
PubMed/Medline, the Centre for Reviews and Dissemination, the EQUATOR net-
work, and websites of health technology assessment agencies and health care
coverage decisionmaking bodies comprehensively identified publicly accessible HE
guidelines. Thesewere categorized as jurisdictionalmandatory, jurisdictional non-
mandatory or general guidelines. Data was extracted into a template devised to
capture 30 fields of content. Both qualitative and quantitative analyses were
performed. RESULTS: Seventy-four HE guidelines were obtained: 23 jurisdictional
mandatory, 11 jurisdictional non-mandatory and 40 general. The most common
topics addressed by guidelines were: sensitivity analysis (by 91%), data identifica-
tion (89%), perspective (84%), choice of health outcomes (82%), assumptions (78%),
valuation of resources (77%), types of costs (76%)/resources to include (74%), com-
parators (74%) and modeling (74%). Compared to jurisdictional guidelines, general
guidelines focused on a narrower range of topics (e.g., modeling) and were less
prescriptive. Although there was a level of agreement on many issues, areas of
divergence were identified: study perspective (emphasis on society: 32% of guide-
lines; health care payer: 19%), unrelated costs in life-years gained (inclusion in
base-case or sensitivity analysis recommended by 8%, exclusion by 7%), methods
to value productivity losses (friction cost approach: 12%; human capital approach:
15%; other: 3%), and recommended type of sensitivity analysis (probabilistic: 28%;
deterministic sufficient: 28%). CONCLUSIONS: Available guidelines for HE evalua-
tions are diverse and cover a broad range of methodological and reporting issues.
Except for specific jurisdictional needs and a few controversial issues, however, there
appears to be convergence of HE guidance over time and stability of basic content.
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OBJECTIVES: To validate the recently updated Charlson Comorbidity Index (CCI)
for the prediction of future healthcare utilization for diabetic patients.METHODS:
Administrative claims data were obtained for diabetic patients enrolled continu-
ously for three years in the Department of Defense TRICARE program for retrospec-
tive analysis. The updated and the original CCI scores were calculated using base-
line year data. Linear regression models were used to estimate log-transformed
healthcare expenditures (COST) for one- and two-year post-index periods. Zero-
inflated negative binomial regressionmodels were used to estimate the number of
hospitalizations (HOS) and the number of emergency department visits (ED) for
one- and two-year post-index periods. The outcome variables were then dichoto-
mized (above or below the 90th percentile of COST; 1HOS or none; 1 ED or none)
and estimated using logistic regression models. Adjusted R®, Akaike information
criteria (AIC), and c statistics were assessed to compare the two CCI versions.
RESULTS:A total of 8,704 patientswere included in the study. The study population
had a mean age of 51.0 years (SD: 10.5), and 46.3 percent were male. In the linear
regression models, the updated CCI explained more variance than the original CCI
in one-year COST (adjusted R® 13.0%vs. 11.3%) and two-year COST (adjusted R®
15.7% vs. 13.9%), adjusting for age and sex. The updated CCI was a better predictor
of one- and two-year HOS (AIC 8581, 13821) as well as one- and two-year ED (AIC
 17009, 25200). In the logistic regressionmodels, the updatedCCI performedbetter
in predicting all study outcomes (c 0.619 to 0.754) than the original CCI (c 0.611
to 0.737). CONCLUSIONS: In a population of diabetic patients, the updated CCI
showed improved predictive performance compared to the original CCI. The up-
dated CCI should be validated in other patient populations.
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OBJECTIVES: To evaluate the performance of diagnosis based and prescription
based comorbiditymeasures in predicting total health care expenditure in patients
with dementia. METHODS: This cross-sectional study was conducted using the
household and medical provider component files of Medical Expenditure Panel
Survey (MEPS) data from 2000 to 2003 (panel 5, 6, and 7). Dementia patients were
identified using cccodex and International Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9CM) codes. Total health care expenditure was defined
as the sumof inpatient, outpatient and pharmacy costs. The comorbiditymeasures
evaluated were diagnosis based scales (identified using ICD-9CM codes): D’Hoore’s
adaptation of Charlson comorbidity index (CCI), and Elixhauser comorbidity algo-
rithm; and prescription based scales (identified using national drug codes): Chronic
Disease Score (CDS-1 and CDS-2). The performance of comorbidity measures was
compared using the adjusted R® derived from multiple linear regression models
that included baseline demographic (age, race, sex) socio-economic (income, in-
surance, geographic region), and perceived health status variables. The perfor-
mance of combined diagnoses and prescription-based scores was also compared.
RESULTS: The adjusted R2 of the baseline model was 0.1464. Model performance
after the addition of comorbiditymeasureswas: Elixhauser (0.3326), CDS-2 (0.3427),
Charlson/D’Hoore (0.2184), and CDS-1 (0.2388). The performance of combined di-
agnosis and prescription based measures was: CDS-2/Elixhauser (0.4356), CDS
1/Elixhauser (0.3979), CDS-2/D’Hoore (0.3493) and CDS-1/D’Hoore (0.2573).
CONCLUSIONS: The Elixhauser and CDS-2 comorbidity measures combined had
the highest prediction of health care expenditure in patients with dementia. The
improvement in risk adjustment from the combination of diagnosis and prescrip-
tion based measures indicates that these different types of measures may be cap-
turing different aspects of the construct of comorbidity, constructs other than
comorbidity, or both.
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BOOTSTRAPPING USED TO PROVIDE ROBUST MEAN AND VARIANCE
ESTIMATES FOR COMPARING PATIENTS TREATED WITH LIRAGLUTIDE TO A
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OBJECTIVES: In an analyses of patients with type 2 diabetes (T2DM) in a large
electronic medical record (EMR) database, small differences were found to be sta-
tistically significant betweenN1162 patientswith liraglutide versus a comparison
cohort due to the comparison group sample size (n274,922). The purpose of this
study is to evaluate a bootstrapping technique to provide robust mean and vari-
ance estimates for comparison patients, thereby helping to address the issue of
being over-powered. METHODS: Study patients were age 18 years with T2DM,
prescribed liraglutide or other antidiabetic drug January 1, 2010 to July 16, 2010 and
with13 months of EMR activity. Bootstrapping was used to provide cohort mean,
standard deviation, and 95% CI estimates for the comparison cohort and were
calculated as the mean of the mean values identified in 1000 random draws with
replacement of 1162 comparison patients. Means (95% CI) were compared for con-
tinuous variables (age, HbA1c and blood pressure [BP]) for liraglutide versus the
overall comparison group and to bootstrap estimates. RESULTS:Of 1162 liraglutide
patients, mean (95% CI) age was 55.5 (54.9, 56.2) years versus 60.9 (60.8, 60.9) years
for all comparison patients and 60.9 (60.1, 61.6) years for comparison patients per
bootstrap estimates (both p0.05). HbA1c was 8.12% (8.00, 8.24) for liraglutide ver-
sus 7.62% (7.61, 7.63) and 7.63% (7.49, 7.76) for all comparison patients and per
bootstrap, respectively (both p0.05). BP was 127.0 (126.1, 127.8)/75.8 (75.3, 76.4)
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